28/01/2023
In India, the second most frequent cancer among women aged 15 to 44 years is cervical cancer. Most cervical cancers are caused by the human papillomavirus, and are sexually transmitted.
Repost
Adar Poonawalla, CEO of vaccine maker Serum Institute of India, announced the launch of the first home-made HPV vaccine. The launch took place in the presence of Home Minister Amit Shah, Adar Poonawalla, and Director of Government & Regulatory Affairs at Serum Institute of India, Prakash K Singh.
Despite being mostly avoidable, cervical cancer ranks as the second most common disease in India and is responsible for approximately one-fourth of all cervical cancer fatalities worldwide. Most cervical cancers are caused by the Human Papilloma Virus (HPV), and the HPV vaccine can prevent most incidences of cervical cancer if given to girls or women before they are exposed to the virus.
In September 2022, SII announced the scientific completion of the cervical cancer vaccine.
Poonawalla, earlier at the World Economic Forum 2023 in Davos, said that the company spent about six to seven years to develop the HPV vaccine.
He also said that the HPV vaccine will be an affordable one and will be rolled out in high capacity to overcome existing market shortages.
According to the US National Institute of Health's (NIH's) National Cancer Institute, three vaccines that prevent infection with disease-causing HPV are currently being marketed in many countries throughout the world. These are Gardasil, Gardasil 9, and Cervarix.
Gardasil is a quadrivalent vaccine, Gardasil 9 is a nonavalent vaccine, and Cervarix is a bivalent vaccine. This means that Gardasil, Gardasil 9, and Cervarix contain four, nine, and two strains of HPV, respectively.
According to Mayo Clinic, males who are vaccinated against the type of HPV associated with cervical cancer may help protect females from the virus by possibly decreasing the risk of transmission.